{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:19:19Z","timestamp":1791317959714,"version":"4.3.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-04813-6","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T03:07:21Z","timestamp":1747624041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prevalence and determinants of apparent treatment-resistant hypertension among patients in South African primary care: a single-centre observational study"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8371-0574","authenticated-orcid":false,"given":"Kellicia Courtney","family":"Govender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4287-1168","authenticated-orcid":false,"given":"Mergan","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"4","key":"4813_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","volume":"16","author":"KT Mills","year":"2020","unstructured":"Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223\u201337.","journal-title":"Nat Rev Nephrol"},{"key":"4813_CR2","doi-asserted-by":"crossref","unstructured":"Gafane-Matemane LF, Craig A, Kruger R, Alaofin OS, Ware LJ, Jones ESW et al. Hypertension in sub-Saharan Africa: the current profile, recent advances, gaps, and priorities. J Hum Hypertens. 2024.","DOI":"10.1038\/s41371-024-00913-6"},{"issue":"5","key":"4813_CR3","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","volume":"72","author":"RM Carey","year":"2018","unstructured":"Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: A scientific statement from the American heart association. Hypertension. 2018;72(5):e53\u201390.","journal-title":"Hypertension"},{"issue":"8","key":"4813_CR4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/jhh.2013.140","volume":"28","author":"E Judd","year":"2014","unstructured":"Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens. 2014;28(8):463\u20138.","journal-title":"J Hum Hypertens"},{"key":"4813_CR5","doi-asserted-by":"crossref","unstructured":"Flack JM, Buhnerkempe MG, Moore KT. Resistant hypertension: disease burden and emerging treatment options. Current Hypertension Reports; 2024.","DOI":"10.1007\/s11906-023-01282-0"},{"issue":"13","key":"4813_CR6","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","volume":"125","author":"SL Daugherty","year":"2012","unstructured":"Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635\u201342.","journal-title":"Circulation"},{"key":"4813_CR7","doi-asserted-by":"crossref","unstructured":"Sim JJ, Bhandari SK, Shi J, Liu IL, Calhoun DA, McGlynn EA, et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013;88(10):1099\u2013107.","DOI":"10.1016\/j.mayocp.2013.06.017"},{"issue":"6","key":"4813_CR8","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1161\/HYPERTENSIONAHA.111.170308","volume":"57","author":"SD Persell","year":"2011","unstructured":"Persell SD. Prevalence of resistant hypertension in the united States, 2003\u20132008. Hypertension. 2011;57(6):1076\u201380.","journal-title":"Hypertension"},{"issue":"3","key":"4813_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/ajh\/hpu151","volume":"28","author":"D Achelrod","year":"2015","unstructured":"Achelrod D, Wenzel U, Frey S. Systematic review and Meta-Analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens. 2015;28(3):355\u201361.","journal-title":"Am J Hypertens"},{"issue":"2","key":"4813_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","volume":"105","author":"JJ Noubiap","year":"2019","unstructured":"Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105(2):98\u2013105.","journal-title":"Heart"},{"issue":"9","key":"4813_CR11","doi-asserted-by":"publisher","first-page":"e011452","DOI":"10.1136\/bmjopen-2016-011452","volume":"6","author":"JRN Nansseu","year":"2016","unstructured":"Nansseu JRN, Noubiap JJN, Mengnjo MK, Aminde LN, Essouma M, Jingi AM, et al. The highly neglected burden of resistant hypertension in Africa: a systematic review and meta-analysis. BMJ Open. 2016;6(9):e011452.","journal-title":"BMJ Open"},{"key":"4813_CR12","doi-asserted-by":"crossref","unstructured":"Moosa MS, Kuttschreuter LS, Rayner BL. Evaluation and management of patients referred to a tertiary-level hypertension clinic in cape town, South Africa. South Afr Med J. 2016;106(8).","DOI":"10.7196\/SAMJ.2016.v106i8.9610"},{"issue":"2","key":"4813_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/16089677.2021.2002585","volume":"27","author":"S Pillay","year":"2021","unstructured":"Pillay S. Hypertension and diabetes mellitus: a collision of two heavyweight non-communicable diseases. J Endocrinol Metabolism Diabetes South Afr. 2021;27(2):57\u201369.","journal-title":"J Endocrinol Metabolism Diabetes South Afr"},{"issue":"5","key":"4813_CR14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1177\/2047487318823575","volume":"26","author":"JD Spence","year":"2019","unstructured":"Spence JD. Hypertension in Africa. Eur J Prev Cardiol. 2019;26(5):455\u20137.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"4813_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/HJH.0000000000001171","volume":"35","author":"BL Rayner","year":"2017","unstructured":"Rayner BL, Spence JD. Hypertension in Blacks: insights from Africa. J Hypertens. 2017;35(2):234\u20139.","journal-title":"J Hypertens"},{"key":"4813_CR16","doi-asserted-by":"crossref","unstructured":"Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR et al. Resistant hypertension: detection, evaluation, and management: A scientific statement from the American heart association. Hypertension. 2018;72(5).","DOI":"10.1161\/HYP.0000000000000084"},{"issue":"1","key":"4813_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41371-024-00983-6","volume":"39","author":"L Faconti","year":"2025","unstructured":"Faconti L, George J, Partridge S, Maniero C, Sathyanarayanan A, Kulkarni S, et al. Investigation and management of resistant hypertension: British and Irish hypertension society position statement. J Hum Hypertens. 2025;39(1):1\u201314.","journal-title":"J Hum Hypertens"},{"issue":"1","key":"4813_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40885-023-00255-4","volume":"29","author":"S Park","year":"2023","unstructured":"Park S, Shin J, Ihm SH, Kim KI, Kim HL, Kim HC, et al. Resistant hypertension: consensus document from the Korean society of hypertension. Clin Hypertens. 2023;29(1):30.","journal-title":"Clin Hypertens"},{"issue":"9","key":"4813_CR19","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1038\/s41440-024-01785-6","volume":"47","author":"P Chattranukulchai","year":"2024","unstructured":"Chattranukulchai P, Roubsanthisuk W, Kunanon S, Kotruchin P, Satirapoj B, Wongpraparut N, et al. Resistant hypertension: diagnosis, evaluation, and treatment a clinical consensus statement from the Thai hypertension society. Hypertens Res. 2024;47(9):2447\u201355.","journal-title":"Hypertens Res"},{"issue":"7","key":"4813_CR20","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/bcp.14193","volume":"86","author":"AHY Chan","year":"2020","unstructured":"Chan AHY, Horne R, Hankins M, Chisari C. The medication adherence report scale: A measurement tool for eliciting patients\u2019 reports of nonadherence. Br J Clin Pharmacol. 2020;86(7):1281\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"4813_CR21","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1378\/chest.15-0903","volume":"149","author":"F Chung","year":"2016","unstructured":"Chung F, Abdullah HR, Liao P, STOP-Bang Questionnaire. A practical approach to screen for obstructive sleep apnea. Chest. 2016;149(3):631\u20138.","journal-title":"Chest"},{"key":"4813_CR22","doi-asserted-by":"crossref","unstructured":"Klug EQ, Raal FJ, Marais AD, Smuts CM, Shamroth C, Jankelow D, Klug E, Raal FJ, Marais AD et al. South African Dyslipidaemia Guideline Consensus Statement 2018 Update: A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). S Afr Med J. 2018;108(11b):973\u20131000. South African Medical Journal. 2018;108(11):973\u20131000.","DOI":"10.7196\/SAMJ.2018.v108i11.13383"},{"issue":"6","key":"4813_CR23","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5830\/CVJA-2014-062","volume":"25","author":"YK Seedat","year":"2014","unstructured":"Hypertension guideline working g, Seedat YK, Rayner BL, Veriava Y. South African hypertension practice guideline 2014. Cardiovasc J Afr. 2014;25(6):288\u201394.","journal-title":"Cardiovasc J Afr"},{"issue":"4S","key":"4813_CR24","first-page":"S117","volume":"105","author":"Kidney Disease","year":"2024","unstructured":"Kidney Disease. Improving global outcomes CKDWG. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314.","journal-title":"Kidney Int"},{"issue":"20","key":"4813_CR25","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3390\/healthcare11202783","volume":"11","author":"A Makukule","year":"2023","unstructured":"Makukule A, Modjadji P, Thovhogi N, Mokgalaboni K, Kengne AP. Uncontrolled hypertension, treatment, and predictors among hypertensive Out-Patients attending primary health facilities in Johannesburg, South Africa. Healthcare. 2023;11(20):2783.","journal-title":"Healthcare"},{"issue":"7","key":"4813_CR26","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1097\/HJH.0000000000001729","volume":"36","author":"A de la Sierra","year":"2018","unstructured":"de la Sierra A, Armario P, Oliveras A, Banegas JR, Gorostidi M, Vinyoles E, et al. Antihypertensive drug use in resistant and nonresistant hypertension and in controlled and uncontrolled resistant hypertension. J Hypertens. 2018;36(7):1563\u201370.","journal-title":"J Hypertens"},{"issue":"9","key":"4813_CR27","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/jch.13974","volume":"22","author":"NK Ayisi-Boateng","year":"2020","unstructured":"Ayisi-Boateng NK, Mohammed A, Opoku DA, Sarfo FS. Frequency & factors associated with apparent resistant hypertension among Ghanaians in a multicenter study. J Clin Hypertens. 2020;22(9):1594\u2013602.","journal-title":"J Clin Hypertens"},{"issue":"9","key":"4813_CR28","doi-asserted-by":"publisher","first-page":"e1441","DOI":"10.1002\/hsr2.1441","volume":"6","author":"M Elbarbary","year":"2023","unstructured":"Elbarbary M, Shoeib O, El-Saied SB, Atlm RM, Alkassas A. Prevalence and determinants of resistant hypertension in the delta region of Egypt: A prospective observational study. Health Sci Rep. 2023;6(9):e1441.","journal-title":"Health Sci Rep"},{"key":"4813_CR29","doi-asserted-by":"crossref","unstructured":"Abiodun OO, Anya T, Chukwu JC, Adekanmbi V, Prevalence. Risk factors and cardiovascular comorbidities of resistant hypertension among treated hypertensives in a Nigerian population. Global Heart. 2024;19(1).","DOI":"10.5334\/gh.1296"},{"key":"4813_CR30","doi-asserted-by":"crossref","unstructured":"Yeo JJP, Yeo LS et al. Shirley Siang Ning Tan, Dayang Diana Rozana Aini Delailah, Shaun Wen Huey Lee, Anna Ting Huey Hu,. Prevalence of true resistant hypertension in those referred for uncontrolled hypertension in Malaysia: A comparison using different definitions. Hypertens Res. 2024;47:352-7.","DOI":"10.1038\/s41440-023-01418-4"},{"issue":"3","key":"4813_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/pds.4388","volume":"27","author":"L Holmqvist","year":"2018","unstructured":"Holmqvist L, Bostrom KB, Kahan T, Schioler L, Qvarnstrom M, Wettermark B, et al. Drug adherence in treatment resistant and in controlled hypertension-Results from the Swedish primary care cardiovascular database (SPCCD). Pharmacoepidemiol Drug Saf. 2018;27(3):315\u201321.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4813_CR32","doi-asserted-by":"crossref","unstructured":"Chan KK, Chiang L, Choi CC, Li Y, Chen CX. Prevalence and associated risk factors of resistant hypertension among Chinese hypertensive patients in primary care setting. BMC Prim Care. 2024;25(1).","DOI":"10.1186\/s12875-024-02366-9"},{"issue":"671","key":"4813_CR33","doi-asserted-by":"publisher","first-page":"e394","DOI":"10.3399\/bjgp18X696221","volume":"68","author":"P Hayes","year":"2018","unstructured":"Hayes P, Casey M, Glynn LG, Molloy GJ, Durand H, O\u2019Brien E, et al. Prevalence of treatment-resistant hypertension after considering pseudo-resistance and morbidity: a cross-sectional study in Irish primary care. Br J Gen Pract. 2018;68(671):e394\u2013400.","journal-title":"Br J Gen Pract"},{"issue":"7","key":"4813_CR34","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.amjmed.2015.02.008","volume":"128","author":"VJ Howard","year":"2015","unstructured":"Howard VJ, Tanner RM, Anderson A, Irvin MR, Calhoun DA, Lackland DT, et al. Apparent Treatment-resistant hypertension among individuals with history of stroke or transient ischemic attack. Am J Med. 2015;128(7):707\u2013e142.","journal-title":"Am J Med"},{"issue":"12","key":"4813_CR35","first-page":"1286","volume":"25","author":"ES Jones","year":"2012","unstructured":"Jones ES, Owen EP, Rayner BL. The association of the R563Q genotype of the ENaC with phenotypic variation in Southern Africa. Am J Hypertens. 2012;25(12):1286\u201391.","journal-title":"Am J Hypertens"},{"issue":"5","key":"4813_CR36","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/ajh\/hpw167","volume":"30","author":"ES Jones","year":"2017","unstructured":"Jones ES, Spence JD, Mcintyre AD, Nondi J, Gogo K, Akintunde A, et al. High frequency of variants of candidate genes in black Africans with low Renin-Resistant hypertension. Am J Hypertens. 2017;30(5):478\u201383.","journal-title":"Am J Hypertens"},{"issue":"9","key":"4813_CR37","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/ajh\/hpx066","volume":"30","author":"A Akintunde","year":"2017","unstructured":"Akintunde A, Nondi J, Gogo K, Jones ESW, Rayner BL, Hackam DG, et al. Physiological phenotyping for personalized therapy of uncontrolled hypertension in Africa. Am J Hypertens. 2017;30(9):923\u201330.","journal-title":"Am J Hypertens"},{"issue":"9","key":"4813_CR38","doi-asserted-by":"publisher","first-page":"632","DOI":"10.7196\/SAMJ.2019.v109i9.14158","volume":"109","author":"BL Rayner","year":"2019","unstructured":"Rayner BL, Spence JD, Bryer A, Mpe MT. Registration of Amiloride in South Africa: cutting the gordian knot. South Afr Med J. 2019;109(9):632.","journal-title":"South Afr Med J"},{"issue":"6","key":"4813_CR39","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/hr.2013.30","volume":"36","author":"ML Muiesan","year":"2013","unstructured":"Muiesan ML, Salvetti M, Rizzoni D, Paini A, Agabiti-Rosei C, Aggiusti C, et al. Resistant hypertension and target organ damage. Hypertens Res. 2013;36(6):485\u201391.","journal-title":"Hypertens Res"},{"issue":"6","key":"4813_CR40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jash.2010.10.003","volume":"4","author":"C Cuspidi","year":"2010","unstructured":"Cuspidi C, Vaccarella A, Negri F, Sala C. Resistant hypertension and left ventricular hypertrophy: an overview. J Am Soc Hypertens. 2010;4(6):319\u201324.","journal-title":"J Am Soc Hypertens"},{"issue":"1","key":"4813_CR41","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1161\/01.HYP.0000169972.96201.8e","volume":"46","author":"MH Drazner","year":"2005","unstructured":"Drazner MH, Dries DL, Peshock RM, Cooper RS, Klassen C, Kazi F, et al. Left ventricular hypertrophy is more prevalent in Blacks than Whites in the general population: the Dallas heart study. Hypertension. 2005;46(1):124\u20139.","journal-title":"Hypertension"},{"key":"4813_CR42","doi-asserted-by":"crossref","unstructured":"Khalfallah M, Elsheikh A, Eissa A, Elnagar B. Prevalence, predictors, and outcomes of resistant hypertension in Egyptian population. Global Heart. 2023;18(1).","DOI":"10.5334\/gh.1211"},{"key":"4813_CR43","doi-asserted-by":"publisher","first-page":"1200952","DOI":"10.3389\/fmed.2023.1200952","volume":"10","author":"AM Ahmed","year":"2023","unstructured":"Ahmed AM, Nur SM, Xiaochen Y. Association between obstructive sleep apnea and resistant hypertension: systematic review and meta-analysis. Front Med (Lausanne). 2023;10:1200952.","journal-title":"Front Med (Lausanne)"},{"key":"4813_CR44","doi-asserted-by":"publisher","first-page":"137","DOI":"10.25259\/JPATS_9_2023","volume":"4","author":"NI Nwosu","year":"2023","unstructured":"Nwosu NI, Ufoaroh CU, Nwaneli CU, Anyim OB, Umeh CR, Ukemenam WC. High risk of obstructive sleep apnea among hypertensive patients in two tertiary centers in Nigeria. J Pan Afr Thorac Soc. 2023;4:137\u201345.","journal-title":"J Pan Afr Thorac Soc"},{"issue":"4","key":"4813_CR45","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1291\/hypres.31.607","volume":"31","author":"ESFR Muxfeldt","year":"2008","unstructured":"Muxfeldt ESFR, Castelpoggi CH, Salles GF. Ambulatory arterial stiffness index or pulse pressure: which correlates better with arterial stiffness in resistant hypertension?? Hypertens Res. 2008;31(4):607\u201313.","journal-title":"Hypertens Res"},{"issue":"9","key":"4813_CR46","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/jhh.2010.95","volume":"25","author":"LC Martins","year":"2010","unstructured":"Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JFV, et al. Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens. 2010;25(9):532\u20138.","journal-title":"J Hum Hypertens"},{"issue":"3","key":"4813_CR47","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1161\/01.HYP.0000116223.97436.e5","volume":"43","author":"TL Goodfriend","year":"2004","unstructured":"Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004;43(3):518\u201324.","journal-title":"Hypertension"},{"issue":"10008","key":"4813_CR48","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, Bisoprolol, and Doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059\u201368.","journal-title":"Lancet"},{"issue":"1","key":"4813_CR49","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/cvr\/cvad165","volume":"120","author":"Z Tian","year":"2024","unstructured":"Tian Z, Vollmer Barbosa C, Lang H, Bauersachs J, Melk A, Schmidt BMW. Efficacy of Pharmacological and interventional treatment for resistant hypertension: a network meta-analysis. Cardiovasc Res. 2024;120(1):108\u201319.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"4813_CR50","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/HYPERTENSIONAHA.111.180497","volume":"58","author":"MR Hanselin","year":"2011","unstructured":"Hanselin MR, Saseen JJ, Allen RR, Marrs JC, Nair KV. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension. 2011;58(6):1008\u201313.","journal-title":"Hypertension"},{"issue":"6","key":"4813_CR51","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1161\/HYPERTENSIONAHA.116.08128","volume":"68","author":"AY Hwang","year":"2016","unstructured":"Hwang AY, Dave C, Smith SM. Trends in antihypertensive medication use among US patients with resistant hypertension, 2008 to 2014. Hypertension. 2016;68(6):1349\u201354.","journal-title":"Hypertension"},{"issue":"3","key":"4813_CR52","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.nefroe.2022.12.002","volume":"43","author":"I Galceran","year":"2023","unstructured":"Galceran I, Vazquez S, Crespo M, Pascual J, Oliveras A. Hypertensive mediated organ damage evolution in resistant hypertension patients after adding spironolactone. Nefrologia (Engl Ed). 2023;43(3):309\u201315.","journal-title":"Nefrologia (Engl Ed)"},{"key":"4813_CR53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejim.2024.04.011","volume":"126","author":"A Coca","year":"2024","unstructured":"Coca A, Whelton SP, Camafort M, L\u00f3pez-L\u00f3pez JP, Yang E. Single-pill combination for treatment of hypertension: just a matter of practicality or is there a real clinical benefit? Eur J Intern Med. 2024;126:16\u201325.","journal-title":"Eur J Intern Med"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04813-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04813-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04813-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T04:03:14Z","timestamp":1747627394000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04813-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4813"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04813-6","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The University of KwaZulu-Natal Biomedical Research and Ethics Committee (BREC\/00005737\/2023), together with the Kwa-Zulu Natal Department of Health and Wentworth Hospital management, granted ethical clearance for this study. Clinical trial number: not applicable. All participants provided written informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"373"}}